Dana-Farber Cancer Institute to investigate Chemokine Therapeutics' CTCE-9908 in a preclinical study of human brain cancer
21-Feb-2006 -
Chemokine Therapeutics Corp. announced that it has executed a Material Transfer Agreement with the Dana-Farber Cancer Institute of Boston, Massachusetts. Chemokine Therapeutics will supply Dana-Farber with its lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist. Oncologists at ...
angiogenesis
brain cancer
Expression
+4